Profile data is unavailable for this security.
About the company
Ourofino SA, formerly Ouro Fino Saude Animal Participacoes SA is a Brazil-based company engaged in the veterinary industry. The Company’s activities are divided into three categories: production animals; companion animals; and international operations. The production animals segment represents the manufacture and sale in the domestic market of vaccines and veterinary products for animals, including ruminants, poultry, swine and horses. The companion animal segment is responsible for the manufacture and sale of veterinary products for dogs and cats. The Company’s portfolio includes otological, dermatological, nutritional, antibiotic, anti-inflammatory, antiparasitic products, as well as diagnostic kits and disinfectants. The international operations segment represents the production of vaccines and veterinary products for the foreign market, including Mexico and Colombia.
- Revenue in BRL (TTM)1.15bn
- Net income in BRL824.06m
- Incorporated2014
- Employees1.01k
- LocationOurofino SARodovia Anhanguera SP 330Km 298, Distrito Industrial, Cravinhos 14.140-000BrazilBRA
- Phone+55 1 635184098
- Fax+55 1 635182000
- Websitehttps://ourofino.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cutia Therapeutics | 189.34m | -357.20m | 1.25bn | 298.00 | -- | 1.93 | -- | 6.60 | -1.70 | -1.70 | 0.9023 | 2.67 | 0.1908 | 2.55 | 5.57 | 851,414.80 | -36.00 | -- | -44.42 | -- | 34.92 | -- | -188.66 | -- | 2.92 | -- | 0.2774 | -- | 103.17 | -- | 77.91 | -- | -- | -- |
| IOL Chemicals and Pharmaceuticals Ltd | 949.32m | 54.94m | 1.26bn | 2.89k | 23.00 | -- | 14.27 | 1.33 | 3.25 | 3.25 | -- | -- | -- | -- | -- | 5,696,991.00 | -- | 10.26 | -- | 13.42 | 34.43 | 32.57 | 5.79 | 9.33 | -- | 8.05 | -- | 13.68 | -2.51 | 1.88 | -24.82 | -22.49 | 21.61 | 5.92 |
| Zhaoke Ophthalmology Ltd | 26.74m | -210.50m | 1.27bn | 270.00 | -- | 0.9779 | -- | 47.34 | -0.5698 | -0.5698 | 0.0725 | 3.54 | 0.0159 | 1.38 | 9.25 | 136,211.20 | -12.50 | -38.02 | -14.65 | -41.79 | 49.28 | -- | -787.13 | -4,412.89 | 4.36 | -29.83 | 0.1373 | -- | 269.73 | -- | 38.32 | -- | 18.80 | -- |
| Solara Active Pharma Sciences Ltd | 723.20m | -11.01m | 1.27bn | 1.78k | -- | -- | 28.01 | 1.76 | -4.81 | -4.81 | 330.32 | -- | -- | -- | -- | 7,068,733.00 | -- | -3.27 | -- | -5.35 | 51.77 | 39.95 | -1.52 | -6.17 | -- | 0.7946 | -- | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
| Adimmune Corp | 199.49m | -84.47m | 1.29bn | 564.00 | -- | 1.61 | -- | 6.45 | -1.21 | -1.21 | 2.85 | 11.21 | 0.1413 | 1.43 | 2.11 | -- | -7.07 | 0.5893 | -8.86 | 0.6742 | 2.67 | 32.30 | -50.05 | 2.71 | 1.42 | -49.73 | 0.4028 | 31.00 | -12.78 | 3.68 | 62.06 | -- | -15.71 | -- |
| Ourofino SA | 1.15bn | 824.06m | 1.29bn | 1.01k | 1.56 | 1.80 | 1.49 | 1.12 | 15.33 | 15.33 | 21.42 | 13.25 | 0.8321 | 1.68 | 3.86 | -- | 59.53 | 18.16 | 72.62 | 22.79 | 50.93 | 49.52 | 71.54 | 23.66 | 2.19 | 35.84 | 0.4107 | 14.57 | 8.64 | 10.59 | 1,729.59 | 77.46 | -3.03 | 36.23 |
| Euroapi SA | 5.47bn | -770.01m | 1.30bn | 3.43k | -- | 0.2187 | -- | 0.2371 | -1.31 | -1.31 | 9.33 | 10.01 | 0.5453 | 1.29 | 5.67 | 257,526.30 | -7.68 | -4.32 | -11.36 | -5.77 | 13.71 | 14.37 | -14.09 | -7.36 | 0.7994 | -1.65 | 0.0671 | -- | -9.79 | 0.0741 | 31.15 | -- | 5.71 | -- |
| Opus Genetics Inc | 76.38m | -355.99m | 1.31bn | 18.00 | -- | 39.37 | -- | 17.16 | -1.76 | -1.76 | 0.2952 | 0.0925 | 0.3825 | -- | 3.85 | 812,944.40 | -178.28 | -76.30 | -330.00 | -86.90 | -- | -- | -466.09 | -185.79 | -- | -- | 0.1518 | -- | -42.30 | -- | -476.13 | -- | -- | -- |
| Seikagaku Corp | 1.23bn | -25.81m | 1.32bn | 1.08k | -- | 0.5078 | 28.94 | 1.08 | -13.84 | -13.84 | 656.96 | 1,337.18 | 0.4328 | 2.03 | 3.92 | 33,360,930.00 | -0.9099 | 3.60 | -0.9881 | 3.96 | 40.92 | 52.56 | -2.10 | 7.94 | 4.26 | -- | 0.0049 | 55.17 | 8.73 | 6.57 | -44.46 | -- | 18.48 | 2.90 |
| Bliss GVS Pharma Ltd | 500.37m | 62.88m | 1.33bn | 966.00 | 21.39 | -- | 15.65 | 2.65 | 10.18 | 10.18 | 80.97 | -- | -- | -- | -- | 8,986,598.00 | -- | 6.04 | -- | 7.54 | 52.65 | 46.33 | 13.18 | 9.45 | -- | 8.44 | -- | 8.27 | 5.13 | 3.27 | 11.72 | -2.82 | 5.18 | 0.00 |
| Hyloris Pharmaceuticals SA | 45.36m | -39.72m | 1.34bn | 40.00 | -- | 7.46 | -- | 29.44 | -0.229 | -0.229 | 0.2615 | 1.03 | 0.1776 | -- | 1.82 | 180,993.60 | -15.55 | -19.78 | -19.04 | -23.43 | 96.63 | 95.47 | -87.56 | -355.75 | 3.80 | -6.31 | 0.0653 | -- | 305.27 | 147.54 | 58.76 | -- | -24.74 | -- |
Data as of Feb 14 2026. Currency figures normalised to Ourofino SA's reporting currency: Brazilian Real BRL
1.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 30 Jun 2025 | 544.90k | 1.01% |
| Perfin Equities Administra��o de Recursos Ltda.as of 30 Sep 2025 | 336.63k | 0.62% |
| BC Gest�o de Recursos Ltda.as of 30 Sep 2025 | 78.75k | 0.15% |
| Apo Asset Management GmbHas of 31 Mar 2024 | 58.40k | 0.11% |
| Intrag DTVM Ltda.as of 30 Sep 2024 | 21.27k | 0.04% |
| Morgan Stanley Administradora de Carteiras SAas of 30 Sep 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
